Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia

被引:10
作者
Alemayehu, Senait [1 ]
Yigezu, Amanuel [1 ]
Hailemariam, Damen [2 ]
Hailu, Alemayehu [2 ,3 ]
机构
[1] Ethiopian Publ Hlth Inst, Addis Ababa, Ethiopia
[2] Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, Ethiopia
[3] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen Ctr Eth & Prior Setting, Bergen, Norway
来源
PLOS ONE | 2020年 / 15卷 / 07期
关键词
D O I
10.1371/journal.pone.0235820
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background In Ethiopia, MDR-TB has become a significant public health threat; therefore, the Ministry of Health introduced two treatment approaches for MDR-TB cases: treatment initiative center (TIC) and treatment follow-up center (TFC). TIC is where patients usually are diagnosed and start the treatment. At TFC, we follow MDR-TB patients until they completed the treatment. However, there is no evidence about the cost-effectiveness of the approaches. Therefore, this study aimed to analyze the cost-effectiveness of MDR-TB treatment in TIC and TFC. Methods In this study, we employed a full economic evaluation from a providers' perspective. We followed a hypothetical cohort of individuals from the age of 15 for a lifetime using a Markov model with five mutually exclusive health states. We used both primary and secondary data sources for the study. Ingredient-based costing approach was used. The costs include healthcare provider costs (recurrent and capital cost) and patient-side costs (direct and indirect). We use a human capital approach to estimate the indirect cost. The cost estimates were reported in the 2017 United States Dollar (US$), and effectiveness was measured using disability-adjusted life-years (DALYs) averted. Both costs and health benefits were discounted using a 3% discount rate. Both average and incremental cost-effectiveness ratios (ICER) were reported calculated. One-way and probabilistic sensitivity analyses were reported to determine the robustness of the estimates. Results The cost per HIV negative patient successfully treated for MDR-TB was $8,416 at TIC and $6,657 at TFC. The average cost-effectiveness ratio per DALY averted at TFC was $671 and $1,417 per DALY averted at TIC. The incremental cost-effectiveness ratio (ICER) of MDR-TB treatment at TIC was $1,641 per DALYs averted. Conclusion This study indicates that the treatment of MDR-TB at both TIC and TFC are cost-effective interventions compared with the willingness to pay threshold of three-times the GDP per capita in Ethiopia.
引用
收藏
页数:13
相关论文
共 27 条
[1]  
[Anonymous], 2012, COST EFF STRAT PLANN
[2]  
[Anonymous], Global Tuberculosis Report 2016
[3]  
[Anonymous], 2016, CDC 2016, P214
[4]  
[Anonymous], 2017, GLOB TUB REP
[5]  
Baye M. DW, 2018, J INFECT DIS THERAPY, V6, DOI [10.4172/2161-1068.1000194, DOI 10.4172/2161-1068.1000194]
[6]  
Belete G. GA, 2013, BRAZ J INFECT DIS, V17, P8
[7]   Cost and Cost-Effectiveness of Smear-Positive Tuberculosis Treatment by Health Extension Workers in Southern Ethiopia: A Community Randomized Trial [J].
Datiko, Daniel G. ;
Lindtjorn, Bernt .
PLOS ONE, 2010, 5 (02)
[8]  
Donev D., 2010, Methods Tools Public Health, V30, P30
[9]  
Drummond M., 2017, METHODS EC EVALUATIO
[10]   A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis [J].
Fitzpatrick, Christopher ;
Floyd, Katherine .
PHARMACOECONOMICS, 2012, 30 (01) :63-80